Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polycan is a water-soluble $\beta$-1,3/1,6-glucan complex of extracellular polysaccharides purified from the *Aureobasidium pullulans* strain SM-2001. Developed by Glucan Co., Ltd., it features a specific molecular structure with $\beta$-1,3 and $\beta$-1,6 linkages in a 68:32 ratio and an average molecular weight of approximately 260 kDa. Polycan acts as an immunomodulator and anti-inflammatory agent, demonstrating the ability to reduce levels of proinflammatory cytokines such as TNF-$\alpha$, IL-6, and IL-1$\beta$, and decrease myeloperoxidase (MPO) activity. In models of ulcerative colitis, it has been shown to protect intestinal barrier function by maintaining tight junction proteins like ZO-1 and occludin, while also modulating the gut microbiota (notably increasing *Akkermansiaceae*) and inhibiting apoptosis. It is recognized as a health functional food ingredient by the KFDA and holds FDA GRAS status, with research extending into osteoarthritis, muscle atrophy, and atopic dermatitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polycan.